About the Authors
- Dirk F. van Helden
-
* E-mail: dirk.vanhelden@newcastle.edu.au
Affiliations School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
- Paul A. Thomas
-
Affiliations School of Medicine, University of Queensland, Brisbane, Queensland, Australia, Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
- Peter J. Dosen
-
Affiliation School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia
- Mohammad S. Imtiaz
-
Affiliation School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia
- Derek R. Laver
-
Affiliation School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia
- Geoffrey K. Isbister
-
Affiliations School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia, Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, Waratah, New South Wales, Australia
Competing Interests
I have read the journal's policy and have the following conflicts: DFvH has an Australian use patent for GTNO. This does not alter our adherence to all PLOS policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: DFvH PAT GKI. Performed the experiments: PJD. Analyzed the data: DFvH. Contributed reagents/materials/analysis tools: MSI DRL. Wrote the paper: DFvH GKI.